160 related articles for article (PubMed ID: 37102523)
1. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
[TBL] [Abstract][Full Text] [Related]
2. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
[TBL] [Abstract][Full Text] [Related]
5. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
[TBL] [Abstract][Full Text] [Related]
6. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
7. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
[TBL] [Abstract][Full Text] [Related]
9. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
Obi Y; Thomas F; Dashputre AA; Goedecke P; Kovesdy CP
Kidney Med; 2024 Jan; 6(1):100757. PubMed ID: 38192434
[TBL] [Abstract][Full Text] [Related]
10. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
Dwyer JP; Agiro A; Desai P; Oluwatosin Y
Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
[TBL] [Abstract][Full Text] [Related]
11. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors.
De Nicola L; Ferraro PM; Montagnani A; Pontremoli R; Dentali F; Sesti G
Intern Emerg Med; 2024 Mar; 19(2):295-306. PubMed ID: 37775712
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
14. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
15. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Gregg LP; Navaneethan SD
Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
[TBL] [Abstract][Full Text] [Related]
16. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia.
Li L; Harrison SD; Cope MJ; Park C; Lee L; Salaymeh F; Madsen D; Benton WW; Berman L; Buysse J
J Cardiovasc Pharmacol Ther; 2016 Sep; 21(5):456-65. PubMed ID: 26856345
[TBL] [Abstract][Full Text] [Related]
19. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.
Morales E; Cravedi P; Manrique J
Front Med (Lausanne); 2021; 8():653634. PubMed ID: 34150795
[TBL] [Abstract][Full Text] [Related]
20. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.
Stawowczyk E; Ward T; Paoletti E; Senni M; de Arellano AR
Cost Eff Resour Alloc; 2024 May; 22(1):42. PubMed ID: 38769560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
